Jyotsna Mullur1, Camille M Steger2, Deborah Gakpo3, Jillian C Bensko3, Rie Maurer2, Tanya M Laidlaw1, Kathleen M Buchheit4. 1. Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, Massachusetts; Department of Medicine, Harvard Medical School, Boston, Massachusetts. 2. Center for Clinical Investigation, Brigham and Women's Hospital, Boston, Massachusetts. 3. Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, Massachusetts. 4. Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, Massachusetts; Department of Medicine, Harvard Medical School, Boston, Massachusetts. Electronic address: kbuchheit@bwh.harvard.edu.
Abstract
BACKGROUND: Patterns of medication use and efficacy in aspirin-exacerbated respiratory disease (AERD) have not been well characterized, especially since the advent of respiratory biologics. Aspirin therapy after desensitization (ATAD) is efficacious for upper and lower respiratory symptoms for patients with AERD, though aspirin-related adverse effects can limit therapy. The optimal coordination of ATAD and respiratory biologics for the treatment of AERD remains unclear. OBJECTIVE: We aimed to characterize patterns of medication use and treatment experience with biologics and ATAD in AERD. METHODS: We surveyed 98 patients with AERD recruited from the Brigham and Women's Hospital AERD registry. Patients completed an online questionnaire describing their medication history and treatment experience. RESULTS: A total of 52 (53.0%) patients reported a history of use of one or more respiratory biologics (omalizumab, mepolizumab, reslizumab, benralizumab, or dupilumab), and 84 (85.7%) reported undergoing aspirin desensitization. There were 24 patients (24.4%) who reported concurrent use of a biologic and ATAD. Compared with those taking ATAD alone, patients taking a biologic and ATAD concurrently were less likely to report that aspirin was effective for their AERD symptoms (odds ratio, 0.161 [95% confidence interval, 0.03-0.76]; P =.02). Whereas patients reported varying efficacy with biologics, dupilumab had the highest odds of patients reporting it worked "very well" (odds ratio, 17.58 [95% confidence interval, 5.68-54.35]; P < .001). CONCLUSION: Biologics are emerging as a treatment option for AERD and are generally well tolerated. Biologic efficacy in AERD is variable by agent, though most patients taking dupilumab found it to be effective. Patients on a biologic in conjunction with ATAD may represent a more severe subset of AERD for which ATAD alone is insufficient.
BACKGROUND: Patterns of medication use and efficacy in aspirin-exacerbated respiratory disease (AERD) have not been well characterized, especially since the advent of respiratory biologics. Aspirin therapy after desensitization (ATAD) is efficacious for upper and lower respiratory symptoms for patients with AERD, though aspirin-related adverse effects can limit therapy. The optimal coordination of ATAD and respiratory biologics for the treatment of AERD remains unclear. OBJECTIVE: We aimed to characterize patterns of medication use and treatment experience with biologics and ATAD in AERD. METHODS: We surveyed 98 patients with AERD recruited from the Brigham and Women's Hospital AERD registry. Patients completed an online questionnaire describing their medication history and treatment experience. RESULTS: A total of 52 (53.0%) patients reported a history of use of one or more respiratory biologics (omalizumab, mepolizumab, reslizumab, benralizumab, or dupilumab), and 84 (85.7%) reported undergoing aspirin desensitization. There were 24 patients (24.4%) who reported concurrent use of a biologic and ATAD. Compared with those taking ATAD alone, patients taking a biologic and ATAD concurrently were less likely to report that aspirin was effective for their AERD symptoms (odds ratio, 0.161 [95% confidence interval, 0.03-0.76]; P =.02). Whereas patients reported varying efficacy with biologics, dupilumab had the highest odds of patients reporting it worked "very well" (odds ratio, 17.58 [95% confidence interval, 5.68-54.35]; P < .001). CONCLUSION: Biologics are emerging as a treatment option for AERD and are generally well tolerated. Biologic efficacy in AERD is variable by agent, though most patients taking dupilumab found it to be effective. Patients on a biologic in conjunction with ATAD may represent a more severe subset of AERD for which ATAD alone is insufficient.
Authors: Mario Castro; Jonathan Corren; Ian D Pavord; Jorge Maspero; Sally Wenzel; Klaus F Rabe; William W Busse; Linda Ford; Lawrence Sher; J Mark FitzGerald; Constance Katelaris; Yuji Tohda; Bingzhi Zhang; Heribert Staudinger; Gianluca Pirozzi; Nikhil Amin; Marcella Ruddy; Bolanle Akinlade; Asif Khan; Jingdong Chao; Renata Martincova; Neil M H Graham; Jennifer D Hamilton; Brian N Swanson; Neil Stahl; George D Yancopoulos; Ariel Teper Journal: N Engl J Med Date: 2018-05-21 Impact factor: 91.245
Authors: Claus Bachert; Joseph K Han; Martin Y Desrosiers; Philippe Gevaert; Enrico Heffler; Claire Hopkins; Jody R Tversky; Peter Barker; David Cohen; Claire Emson; Ubaldo J Martin; Vivian H Shih; Sofia Necander; James L Kreindler; Maria Jison; Viktoria Werkström Journal: J Allergy Clin Immunol Date: 2021-09-29 Impact factor: 14.290
Authors: Kathleen M Buchheit; Erin Lewis; Deborah Gakpo; Jonathan Hacker; Aaqib Sohail; Faith Taliaferro; Evans Berreondo Giron; Chelsea Asare; Marko Vukovic; Jillian C Bensko; Daniel F Dwyer; Alex K Shalek; Jose Ordovas-Montanes; Tanya M Laidlaw Journal: J Allergy Clin Immunol Date: 2021-06-16 Impact factor: 14.290
Authors: Hector G Ortega; Mark C Liu; Ian D Pavord; Guy G Brusselle; J Mark FitzGerald; Alfredo Chetta; Marc Humbert; Lynn E Katz; Oliver N Keene; Steven W Yancey; Pascal Chanez Journal: N Engl J Med Date: 2014-09-08 Impact factor: 91.245